Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CDCA FXR-FGF19 response study in quiescent Crohn's colitis
NL-OMON27642Not yet recruiting
- Sponsor
- P.D. Siersema, MD, PhD, Utrecht, The Netherlands
- Start
- Sep 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of chenodeoxycholic acid in Crohn's disease (2 arms), sponsored by P.D. Siersema, MD, PhD, Utrecht, The Netherlands. Primary endpoint: Change in fasting plasma FGF19 after 8 days of CDCA. Planned start Sep 2009; status: not yet recruiting.
02
Drugs
chenodeoxycholic acid
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NL-OMON27642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON27642.